Med Sheet Digoxin

docx

School

Texas A&M International University *

*We aren’t endorsed by this school

Course

MISC

Subject

Medicine

Date

Apr 3, 2024

Type

docx

Pages

2

Uploaded by LieutenantSardineMaster1088

Report
Part 2 Patient-Specific Information DRUG Time Due: Dose: Frequency: Route: Administration Instructions (specific to route): REASON What is this medication's goal/expected outcome (therapeutic effect)? What evidence from the patient’s chart supports the need for this medication? (i.e., vitals signs, assessment, lab data, medical history, etc.). SAFETY Is this a home medication? If Y is the dose the same? Is the ordered dose safe (according to the safe/usual dose range)? What labs should be assessed prior to administration? Include lab name and client’s lab results (even if normal). Is a dose adjustment required based on the client’s lab results? Based on your client’s other medications, are there any drug-to-drug interactions or IV incompatibilities? Does your client have any of the known contraindications, black box warnings, or adverse effects associated with this medication? ( Support with evidence) If Y, how will you manage these risks? Is the drug safe to administer? Y/N and Why? ( Support with evidence) EVALUATION Did this medication achieve the desired outcome (provide evidence)? What assessment data and labs need to be continuously monitored after the drug is administered? FACULTY SIGNATURE Part 1 Drug-Specific Information (Permission to reuse this portion of form in all courses) Name (Generic/Brand) Digoxin Class (Pharm/Therapeutic) Pharm: Digitalis glycosides Therapeutic: Antiarrhythmics, inotropic Mechanism of Action Increases the force of myocardial contraction. Prolongs refractory period of the AV nodes Increases cardiac output and slowing of the heart rate Onset & Peak PO: Onset 30-120mins Peak: 2-8hrs IM: Onset 30mins Peak: 4-6hrs IV: Onset 5-30mins Peak: 1-4 hrs Indications Heart failure, atrial fibrillation, and atrial flutter Drug Library safe/usual dose range IV, IM (Adults): digitalizing dose – 0.5 – 1 mg given as 50% of the dose initially and one quarter of the initial dose in each of 2 subsequent doses at 6-12 hr intervals PO (Adults): digitalizing dose – 0.75 – 1.5mg given as 50% of the dose initially and one quarter of the initial dose in each of 2 subsequent doses at 6-12 hrs intervals. Maintenance dose – 0.125 – 0.5mg/day depending on the patients lean body weight, renal function, and serum levels Drug-to-Drug Interactions IV Incompatibilities Thiazide and loop diuretics, piperacillin/tazobactam, amphotericin B, corticosteroids, and excessive use of laxatives may cause hypokalemia which may increase risk of toxicity Most Common & Serious Adverse Effects Arrythmias, bradycardia, ECG changes, AV block, SA block, blurred vision, anorexia, nausea, vomiting, fatigue, weakness Contraindications Black Box Warnings Hypersensitivity, uncontrolled ventricular arrythmias, AV block Caution in: hypokalemia (increases risk of digoxin toxicity), hypercalcemia (increases risk of toxicity), hypomagnesemia (risk of toxicity), diuretic use, renal impairment, hypothyroidism Patient Education (Basic Summary) Take med as directed, teach patient to take pulse and to contact HCP before taking med if pulse is <60 or >100. Review S/S of digitalis toxicity, keep digoxin tablets in their original container and not to mix in pill boxes
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
  • Access to all documents
  • Unlimited textbook solutions
  • 24/7 expert homework help